CG Oncology CMO granted 79,216 stock options

CG Oncology, Inc. reported that Chief Medical Officer Kasturi Vijay received an employee stock option grant for 79,216 shares of common stock.

Accepted by SEC EDGAR 04/16/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CG Oncology, Inc. reported that Chief Medical Officer Kasturi Vijay received an employee stock option grant for 79,216 shares of common stock. The option has an exercise price of $67.68 per share, expires on April 14, 2036, and represents a compensation-related award rather than an open-market trade.

These options vest over time: 1/48 of the shares vest monthly after April 15, 2026, as long as Vijay continues providing service to the company. Following this grant, Vijay holds derivative rights to acquire 79,216 shares through this option.

Insider Trade Summary

Grant/Award: 79,216 shares

Grant/Award 1 txn

Insider Kasturi Vijay

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	79,216	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 79,216 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Key Figures

Options granted: 79,216 options Exercise price: $67.68 per share Underlying shares: 79,216 shares +3 more

6 metrics

Options granted 79,216 options Employee stock option grant to CMO Kasturi Vijay

Exercise price $67.68 per share Strike price of employee stock option grant

Underlying shares 79,216 shares Common stock underlying the option award

Expiration date April 14, 2036 Option term end date

Vesting start April 15, 2026 Vesting commencement date; 1/48 vests monthly

Post-grant derivative holdings 79,216 derivative shares Total shares acquirable under this option after grant

Key Terms

Employee Stock Option (Right to Buy), exercise price, underlying security, vesting, +1 more

5 terms

Employee Stock Option (Right to Buy) financial

"security_title: Employee Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 67.6800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"1/48th of the shares subject to the option vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to the Reporting Person's continuous service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CGON’s Chief Medical Officer receive in this Form 4 filing?

The Chief Medical Officer, Kasturi Vijay, received an employee stock option grant for 79,216 shares of CG Oncology common stock. This is a compensation-related award, not an open-market stock purchase or sale, and gives the right to buy shares at a fixed exercise price.

What is the exercise price of the CGON stock options granted to Kasturi Vijay?

The granted employee stock options have an exercise price of $67.68 per share. This means Vijay can buy CG Oncology common shares at $67.68 if and when the options vest and are exercised, regardless of the future market price at that time.

How do the CGON options granted to Kasturi Vijay vest over time?

The options vest in equal monthly installments, with 1/48 of the 79,216 shares vesting each month after April 15, 2026. Vesting continues only if Vijay maintains continuous service with CG Oncology through each applicable vesting date under the grant terms.

When do the CGON stock options granted to Kasturi Vijay expire?

The employee stock options granted to Kasturi Vijay expire on April 14, 2036. After that expiration date, any unexercised options become void, and Vijay would no longer have the right to purchase CG Oncology common stock under this specific grant.

Does this CGON Form 4 show an insider buying or selling shares on the market?

No, the Form 4 reports a grant of employee stock options, not a market trade. Vijay acquired derivative rights to buy 79,216 shares at $67.68 per share as part of compensation, with no open-market buying or selling disclosed in this filing.

How many CGON shares can be acquired through this new option grant?

Through this option grant, Kasturi Vijay can acquire up to 79,216 CG Oncology common shares, subject to vesting. All 79,216 underlying shares are tied to this single option award, and vesting occurs monthly after April 15, 2026, during continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kasturi Vijay

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$67.68	04/15/2026		A		79,216		(1)	04/14/2036	Common Stock	79,216	$0	79,216	D

Explanation of Responses:

1. 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Joshua F. Patterson, Attorney-in-Fact for Vijay Kasturi	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)